In a new study, researchers from the School of Biochemistry and Immunology and the Department of Microbiology at Trinity College Dublin have shown that a protein located on the bacterial surface called clumping factor B (ClfB) has high affinity for the skin protein loricrin.
Staphylococcus aureus (S. Aureus) is a major human pathogen, with the potential to cause severe invasive diseases.
It is a major cause for concern in hospitals and healthcare facilities, where many infections are caused by strains resistant to commonly used antibiotics [MRSA], the study said.
The bacterium S. Aureus persistently colonises about 20 per cent of the human population by binding to skin-like cells within the nasal cavity.
Being colonised predisposes an individual towards becoming infected so it is vital that we understand the mechanisms involved. ClfB was previously shown to promote S. Aureus colonisation in a human nasal colonisation volunteer study.
The study, published in the Open Access journal PLOS Pathogens, identifies the mechanism by which ClfB facilitates S. Aureus nasal colonisation.
Purified ClfB bound loricrin with high affinity and this interaction was shown to be crucial for successful colonization of the nose in a mouse model.
It showed that soluble loricrin could reduce binding of S. aureus to human nasal skin cells and that nasal administration of loricrin reduced S. Aureus colonization of mice.
Rachel McLoughlin, the study's corresponding author and Lecturer at the School of Biochemistry and Immunology at Trinity College Dublin concludes, "Loricrin is a major determinant of S. Aureus nasal colonization."
This discovery opens new avenues for developing therapeutic strategies to reduce the burden of nasal carriage and consequently infections with this bacterium.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
